| PCSK9: from basic science discoveries to clinical trials MD Shapiro, H Tavori, S Fazio Circulation research 122 (10), 1420-1438, 2018 | 258 | 2018 |
| Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation H Tavori, D Fan, JL Blakemore, PG Yancey, L Ding, MRF Linton, S Fazio Circulation 127 (24), 2403-2413, 2013 | 228 | 2013 |
| Local effects of human PCSK9 on the atherosclerotic lesion I Giunzioni, H Tavori, R Covarrubias, AS Major, L Ding, Y Zhang, ... The Journal of pathology 238 (1), 52-62, 2016 | 171 | 2016 |
| Biology of proprotein convertase subtilisin kexin 9: beyond low-density lipoprotein cholesterol lowering GD Norata, H Tavori, A Pirillo, S Fazio, AL Catapano Cardiovascular Research 112 (1), 429-442, 2016 | 144 | 2016 |
| Proprotein Convertase subtilisin kexin Type 9 promotes intestinal overproduction of triglyceride-rich apolipoprotein B lipoproteins through both low-density lipoprotein … S Rashid, H Tavori, PE Brown, MRF Linton, J He, I Giunzioni, S Fazio Circulation 130 (5), 431-441, 2014 | 140 | 2014 |
| PCSK9 association with lipoprotein (a) H Tavori, D Christian, J Minnier, D Plubell, MD Shapiro, C Yeang, ... Circulation research 119 (1), 29-35, 2016 | 123 | 2016 |
| Loss of plasma proprotein convertase subtilisin/kexin 9 (PCSK9) after lipoprotein apheresis H Tavori, I Giunzioni, MRF Linton, S Fazio Circulation research 113 (12), 1290-1295, 2013 | 104 | 2013 |
| Human PCSK9 promotes hepatic lipogenesis and atherosclerosis development via apoE-and LDLR-mediated mechanisms H Tavori, I Giunzioni, IM Predazzi, D Plubell, A Shivinsky, J Miles, ... Cardiovascular research 110 (2), 268-278, 2016 | 100 | 2016 |
| On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effects H Tavori, S Rashid, S Fazio Atherosclerosis 238 (2), 264-270, 2015 | 97 | 2015 |
| Deletion of macrophage low-density lipoprotein receptor-related protein 1 (LRP1) accelerates atherosclerosis regression and increases CC chemokine receptor type 7 (CCR7 … PA Mueller, L Zhu, H Tavori, K Huynh, I Giunzioni, JM Stafford, ... Circulation 138 (17), 1850-1863, 2018 | 89 | 2018 |
| Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects H Tavori, M Aviram, S Khatib, R Musa, S Nitecki, A Hoffman, J Vaya Free Radical Biology and Medicine 46 (5), 607-615, 2009 | 75 | 2009 |
| PMP22 is critical for actin-mediated cellular functions and for establishing lipid rafts S Lee, S Amici, H Tavori, WM Zeng, S Freeland, S Fazio, L Notterpek Journal of Neuroscience 34 (48), 16140-16152, 2014 | 68 | 2014 |
| Relationship between low‐density lipoprotein cholesterol and lipoprotein (a) lowering in response to PCSK9 inhibition with evolocumab MD Shapiro, J Minnier, H Tavori, H Kassahun, A Flower, R Somaratne, ... Journal of the American Heart Association 8 (4), e010932, 2019 | 59 | 2019 |
| Structure-activity relationships of flavonoids V Jacob, T Hagai, K Soliman Current Organic Chemistry 15 (15), 2641-2657, 2011 | 58 | 2011 |
| Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activity H Tavori, S Khatib, M Aviram, J Vaya Bioorganic & medicinal chemistry 16 (15), 7504-7509, 2008 | 54 | 2008 |
| Role of PAI-1 in hepatic steatosis and dyslipidemia JA Levine, C Oleaga, M Eren, AP Amaral, M Shang, E Lux, SS Khan, ... Scientific reports 11 (1), 430, 2021 | 51 | 2021 |
| Glabridin protects paraoxonase 1 from linoleic acid hydroperoxide inhibition via specific interaction: a fluorescence-quenching study D Atrahimovich, J Vaya, H Tavori, S Khatib Journal of agricultural and food chemistry 60 (14), 3679-3685, 2012 | 51 | 2012 |
| Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 (PON1) activity via reaction with PON1 free sulfhydryl cysteine 284 H Tavori, M Aviram, S Khatib, R Musa, D Mannheim, R Karmeli, J Vaya Free Radical Biology and Medicine 50 (1), 148-156, 2011 | 49 | 2011 |
| Loss of macrophage low-density lipoprotein receptor–related protein 1 confers resistance to the antiatherogenic effects of tumor necrosis factor-α inhibition L Zhu, I Giunzioni, H Tavori, R Covarrubias, L Ding, Y Zhang, M Ormseth, ... Arteriosclerosis, thrombosis, and vascular biology 36 (8), 1483-1495, 2016 | 45 | 2016 |
| Vitamin E therapy results in a reduction in HDL function in individuals with diabetes and the haptoglobin 2-1 genotype D Farbstein, S Blum, M Pollak, R Asaf, HL Viener, O Lache, R Asleh, ... Atherosclerosis 219 (1), 240-244, 2011 | 44 | 2011 |
Michael D. ShapiroWake Forest University School of Medicine在 wakehealth.edu 的电子邮件经过验证
